Lipid Research

Preclinical study results show antisense drug inhibits cholesterol in mouse models

Published in Blood Weekly, July 13th, 2006

Isis Pharmaceuticals, Inc. (ISIS) announced results from preclinical studies demonstrating that inhibition of miR-122, a liver-specific microRNA (miRNA), by a second-generation antisense drug significantly improves high cholesterol, fatty liver, and liver function without affecting blood glucose levels in diabetic mouse models.

MiRNAs are a recently discovered class of natural antisense RNAs that are important in the regulation of cellular functions. These data demonstrate that antisense inhibition is a powerful technique to regulate the function of miRNAs and suggest that miR-122 may be an attractive therapeutic target for cardiovascular and metabolic diseases.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2006-07-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry